Capricor Therapeutics reported Q4 2023 revenue of $12.1 million, a net loss of $0.8 million, or $0.02 per share. The company's cash, cash equivalents, and marketable securities totaled approximately $39.5 million as of December 31, 2023.
Enrollment completed in Cohort A of Phase 3 HOPE-3 trial of CAP-1002 in Duchenne Muscular Dystrophy.
Successful interim futility analysis announced.
Type-B meeting with FDA planned in Q1 2024 to discuss commercial manufacturing.
CAP-1002 scale-up expansion underway at new San Diego manufacturing facility.
Capricor anticipates several milestones for its CAP-1002 program and exosome platform, including FDA meetings, data reports, and partnership explorations. They expect current resources to cover expenses into Q1 2025, excluding potential milestone payments.
Analyze how earnings announcements historically affect stock price performance